These results suggested that CXCL9 and αPD-L1 expressed by NPTyr-C9AP not only reinforced T-cell responses but also improved the tumor immune microenvironment, which jointly resulted in enhanced immunotherapy against melanoma. Here, CXCL9 is linked to melanoma.